NASDAQ:GYRE Gyre Therapeutics Q4 2025 Earnings Report $7.95 +0.17 (+2.19%) As of 01:14 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Gyre Therapeutics EPS ResultsActual EPS$0.04Consensus EPS $0.08Beat/MissMissed by -$0.04One Year Ago EPSN/AGyre Therapeutics Revenue ResultsActual Revenue$37.20 millionExpected Revenue$36.30 millionBeat/MissBeat by +$892.00 thousandYoY Revenue GrowthN/AGyre Therapeutics Announcement DetailsQuarterQ4 2025Date3/12/2026TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AUpcoming EarningsGyre Therapeutics' Q1 2026 earnings is estimated for Thursday, May 7, 2026, based on past reporting schedulesConference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Gyre Therapeutics Earnings HeadlinesGyre Therapeutics Completes Acquisition of Cullgen to Create U.S.- and China-based Fully Integrated Biopharmaceutical CompanyMay 4 at 8:47 AM | globenewswire.comGyre Therapeutics Announces China’s NMPA Grants Priority Review to the NDA for Hydronidone (F351) for CHB-Induced Liver Fibrosis TreatmentMarch 17, 2026 | markets.businessinsider.comI was right about SpaceXJeff Brown predicted Bitcoin before it climbed as high as 52,400%, Tesla before 2,150%, and Nvidia before 32,000%. Now he says SpaceX is shaping up to be the biggest IPO of the decade - and three key milestones just confirmed it. In the past 21 days: SpaceX crossed 10,000 active satellites, Elon filed confidential IPO paperwork with the SEC, and another rocket launched 25 more satellites. Two-thirds of every satellite in orbit now belongs to one company. The public filing could drop any day.May 6 at 1:00 AM | Brownstone Research (Ad)Gyre Therapeutics Announces China's NMPA Grants Priority Review to the NDA for Hydronidone (F351) for CHB-Induced Liver Fibrosis TreatmentMarch 17, 2026 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: OptimizeRx (OPRX) and Gyre Therapeutics (GYRE)March 15, 2026 | theglobeandmail.comGyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateMarch 12, 2026 | globenewswire.comSee More Gyre Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Gyre Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Gyre Therapeutics and other key companies, straight to your email. Email Address About Gyre TherapeuticsGyre Therapeutics (NASDAQ:GYRE) is a clinical-stage biotechnology company focused on discovering and developing small-molecule therapies that target lipid biology to treat a range of metabolic, inflammatory and neurodegenerative diseases. The company’s proprietary platform combines lipidomic profiling with drug discovery tools to identify compounds that selectively modulate membrane lipid composition and restore normal protein function in disease-relevant cells. Gyre’s preclinical pipeline includes programs in nonalcoholic steatohepatitis (NASH), Alzheimer’s disease and autoimmune conditions, reflecting its strategy of applying a unified lipid-targeted approach across multiple therapeutic areas. By leveraging its platform to validate novel targets and generate lead candidates, the company aims to address unmet medical needs where dysregulated lipid environments drive disease progression. Headquartered in South San Francisco, California, Gyre Therapeutics was founded in 2021 and completed its initial public offering on the Nasdaq Global Market under the ticker symbol GYRE in mid-2023. Operating primarily in the United States, the company collaborates with academic researchers and industry partners to advance its discovery efforts. Through its innovative focus on membrane biochemistry, Gyre seeks to build a diversified portfolio of first-in-class small-molecule therapies.View Gyre Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Boarding Passes Now Being Issued for the Ultimate eVTOL ArbitrageYears in the Making, AMD’s Upside Movement Has Just BegunWestern Digital: The Storage Behemoth Skyrocketing on AI DemandOld Money, New Tech: Western Union's Crypto RebootPinterest Pins a Profit Play To Its Mood BoardJust How Big a Problem Could Amazon’s Cash Burn Rate Be?BlackBerry Rewrites Its Own Operating System Upcoming Earnings Coinbase Global (5/7/2026)Airbnb (5/7/2026)argenex (5/7/2026)Datadog (5/7/2026)Ferrovial (5/7/2026)Gilead Sciences (5/7/2026)Microchip Technology (5/7/2026)MercadoLibre (5/7/2026)Monster Beverage (5/7/2026)Canadian Natural Resources (5/7/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
